217330 — Cytogen Income Statement
0.000.00%
Last trade - 00:00
- KR₩294bn
- KR₩257bn
- KR₩3bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 799 | 643 | 348 | 761 | 3,184 |
Cost of Revenue | |||||
Gross Profit | -187 | -130 | 57.3 | 195 | 846 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5,287 | 7,230 | 13,206 | 12,068 | 17,171 |
Operating Profit | -4,488 | -6,587 | -12,858 | -11,307 | -13,987 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4,141 | -5,010 | -13,323 | -18,692 | -16,179 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4,141 | -4,889 | -10,871 | -18,771 | -15,770 |
Net Income Before Extraordinary Items | |||||
Net Income | -4,141 | -4,889 | -10,871 | -18,771 | -15,770 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -4,141 | -4,889 | -10,871 | -18,771 | -15,770 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -245 | -289 | -642 | -1,070 | -781 |
Dividends per Share |